AP26113
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AP26113, covering 2017-06-21 to 2017-06-21. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib [Phase 2]